Table 1.
Radiotracers studied in the context of immunotherapy with potential interest, radiotracers, targets and development phase. GLUT-1: glucose transporter 1, NSCLC: non-small cell lung carcinoma.
| Potential Interest | Radiotracers | Targets | Development Phase |
|---|---|---|---|
| Imaging of tumor cells and inflammation | 18F-FDG | GLUT-1 and hexokinase | Market Authorization |
| Imaging of checkpoints inhibitors | 89Zr-Atezolizumab | PD-L1 | Phase I (Lymphoma, Breast cancer, Renal cell carcinoma) |
| 18F-Adnectin | PD-L1 | Preclinical (Rodent) | |
| 18F-PD-L1 ([18F]BMS-986192) | PD-L1 | Phase I/II (Melanoma, NSCLC, Oral cancer) | |
| 99mTc-anti-PD-L1(99m-Tc-NM-01) | PD-L1 | Phase I (NSCLC) | |
| 64Cu-WL12 | PD-L1 | Preclinical (Rodent) | |
| 89Zr-Nivolumab([89Zr]-BMS-936558) | PD-1 | Preclinical (Primate) | |
| 89Zr-Ipilimumab | CTLA-4 | Phase II (Metastatic melanoma) | |
| Imaging of biomarkers of immune response | 89Zr-IFNγ | IFN γ | Preclinical (Rodent) |
| 68Ga-NOTA-GZP | Granzyme | Preclinical (Rodent) | |
| 18F-IL2 ([18F]FB-IL2) | IL2 | Open label (metastatic melanoma); Phase I (renal transplant rejection) | |
| 99mTc-IL2 | IL2 | Phase I (metastatic melanoma) |